IDRA-21 10 MG pellets

IDRA-21 10 MG Pellets – Scientific Description & User Manual

Produktbeskrivelse

IDRA-21 (10 mg pellets)  is a potential  AMPA receptor potentiator  belonging to the class of  nootropic and neuroprotective research chemicals . It works by enhancing glutamate-induced signaling in the brain, which may lead to improved cognitive function, neuroplasticity, and potentially neurorecovery.

These pellets are  highly pure (≥98%) , standardized dosed and intended solely for  scientific research and preclinical studies .

Uses & Applications

IDRA-21 is being studied for its possible effects on:

1. Cognitive Enhancement  – ​​May increase alertness, learning ability, and memory consolidation.

2. Neuroprotection  – Potential protective effect in neurodegenerative diseases (e.g. Alzheimer’s, stroke).

3. Neurological Recovery  – May Promote Synaptic Plasticity After Brain Injury.

4. Scientific Research  – Study of AMPA receptor modulation and glutamate signaling.

⚠ Not approved for human or veterinary use – For in vitro and controlled preclinical studies only.

Dosage & Safety Guidelines

• Investigational dosage (in vitro/preclinical):  5–20 mg/kg  (depending on model).

• Pellet Solution:  Can be dissolved in  distilled water or DMSO  for experiments.

• Administration:  Orally (animal models) or directly in cell cultures.

• Frequency:  Single dose for acute effect; long-term studies require careful monitoring.

🚨 NB:

• No human application  – No safety data for human use.

• High doses may cause neuroexcitotoxicity.

• Avoid combination with other glutamate modulators.

Disadvantages & Risks

• Overstimulation of neurons  (risk of excitotoxicity in case of overdose).

• Possible anxiety or agitation  in susceptible models.

• Limited long-term data  on tolerance and adverse effects.

• Not suitable for chronic use  without extensive toxicity studies.

Ofte stilte spørsmål (FAQ)

1. Is IDRA-21 legal in the Netherlands?

Yes, but only for  vitenskapelig forskning . It doesn’t fall under the Opium Act, but it’s also not approved as a medicine.

2. How exactly does IDRA-21 work?

It  enhances the AMPA receptor response , making glutamate signaling longer and more intense. This can lead to improved synaptic communication.

3. Can IDRA-21 be compared to other nootropics?

It has a unique mechanism of action, but  similar targets as racetams or ampakines  (e.g. Sunifiram).

4. Are there any known interactions?

• NMDA antagonists  (e.g. memantine) – Potentially adverse effects.

• GABAergic agents  (e.g., benzodiazepines) – May reduce anxiolytic effects.

Lab Report & Quality Control

• HPLC analysis:  ≥98% purity .

• No detectable heavy metals or solvent residues .

• Homogeneous pellet formulation  for consistent dosing.

• Batch certification  available for research institutions.

Recommended Research Scenarios

1. Cognitive studies  – Effects on memory and learning in animal models.

2. Neuroprotective research  – Potential role in ischemic injury (stroke models).

3. Electrophysiology  – AMPA receptor response measurements in neuronal cultures.

🔬 For controlled laboratory use only – No recreational use!